论文部分内容阅读
目的 探讨可溶性Fas(sFas)和可溶性FasL(sFasL)在膀胱癌病人尿中的表达及其临床意义。方法 应用双抗体夹心ELISA法检测 4 3例膀胱癌病人术前、术后和 12例正常人尿中sFas和sFasL的表达水平。结果 膀胱癌病人尿sFas和sFasL水平均高于正常对照组 ,sFas与肿瘤临床分期、病理分级正相关 ,sFasL仅与肿瘤临床分期正相关。肿瘤切除术后sFas和sFasL水平均降低 ,而且复发者术后sFas水平显著高于无复发者。结论 sFas和sFasL参与膀胱癌的发生、发展 ,在一定程度上可以反映膀胱癌生物学行为。
Objective To investigate the expression and clinical significance of soluble Fas (sFas) and soluble FasL (sFasL) in bladder of patients with bladder cancer. Methods The expressions of sFas and sFasL in preoperative, postoperative and 12 normal urine of 43 bladder cancer patients were detected by double antibody sandwich ELISA. Results The levels of urinary sFas and sFasL in bladder cancer patients were higher than those in normal control group. The sFas was positively correlated with the clinical stage and pathological grade of tumor, and sFasL was only positively correlated with clinical stage. The levels of sFas and sFasL decreased after tumor resection, and the levels of sFas in relapsed patients were significantly higher than those without recurrence. Conclusion The involvement of sFas and sFasL in the development and progression of bladder cancer can reflect the biological behavior of bladder cancer to a certain extent.